Temazolamide, irinotecan, bevacizumab for glioblastoma – pro
Clinical studies treating pediatric and adult solid tumors, such as glioblastoma (GBM), with a triple-drug regimen of temozolomide (TMZ), bevacizumab (BEV), and irinotecan (IRI) [TBI] have demonstrated various efficacies, but with no unexpected toxicities. I did not find any studies in the front line setting. The study by Lu Guangrong et al was in a recurred/ refractory setting. It was a retrospective study and concluded that the TBI regimen might play a role in the improvement of PFS-R and OS-R among rGBM patients. Prospective studies with a larger sample size are warranted to study the efficacy and toxicity of the TBI+T regimen for rGBM.
Guangrong Lu et al, riple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective StudyFront Neurol . 2019 Jan 31;10:42. doi: 10.3389/fneur.2019.00042. eCollection 2019.